Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TSC2 |
Variant | D514Pfs*74 |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TSC2 D514Pfs*74 indicates a shift in the reading frame starting at amino acid 514 and terminating 74 residues downstream causing a premature truncation of the 1807 amino acid Tsc2 protein (UniProt.org). D514Pfs*74 has not been characterized however, due to the effects of other truncation mutations downstream of D514 (PMID: 22903760, PMID: 31454656), is predicted to lead to a loss of Tsc2 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TSC2 mutant TSC2 inact mut TSC2 D514Pfs*74 |
Transcript | NM_000548.5 |
gDNA | chr16:g.2064368_2064369delGA |
cDNA | c.1540_1541delGA |
Protein | p.D514Pfs*74 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406665.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001363528.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001114382.3 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001370404.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001406663.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_000548.4 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_000548.5 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001406664.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522636.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522640.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_017023615.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522639.3 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522636.3 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001370405.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_005255529.4 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_017023616.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522639.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522637.3 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_024450413.1 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_021055.3 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001114382.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_011522637.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
XM_005255531.4 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001077183.3 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
NM_001077183.2 | chr16:g.2064368_2064369delGA | c.1540_1541delGA | p.D514Pfs*74 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|